NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies

New Hints for NK-Based Immunotherapy?

Claudia Cantoni, Leticia Huergo-Zapico, M. Parodi, Marco Pedrazzi, Maria Cristina Mingari, Alessandro Moretta, B. Sparatore, Segundo Gonzalez, Daniel Olive, Cristina Bottino, Roberta Castriconi, Massimo Vitale

Research output: Contribution to journalReview article

Abstract

Several evidences suggest that NK cells can patrol the body and eliminate tumors in their initial phases but may hardly control established solid tumors. Multiple factors, including the transition of tumor cells towards a proinvasive/prometastatic phenotype, the immunosuppressive effect of the tumor microenvironment, and the tumor structure complexity, may account for limited NK cell efficacy. Several putative mechanisms of NK cell suppression have been defined in these last years; conversely, the cross talk between NK cells and tumor cells undergoing different transitional phases remains poorly explored. Nevertheless, recent in vitro studies and immunohistochemical analyses on tumor biopsies suggest that NK cells could not only kill tumor cells but also influence their evolution. Indeed, NK cells may induce tumor cells to change the expression of HLA-I, PD-L1, or NKG2D-L and modulate their susceptibility to the immune response. Moreover, NK cells may be preferentially located in the borders of tumor masses, where, indeed, tumor cells can undergo Epithelial-to-Mesenchymal Transition (EMT) acquiring prometastatic phenotype. Finally, the recently highlighted role of HMGB1 both in EMT and in amplifying the recruitment of NK cells provides further hints on a possible effect of NK cells on tumor progression and fosters new studies on this issue.

Original languageEnglish
Article number4684268
JournalJournal of Immunology Research
Volume2016
DOIs
Publication statusPublished - 2016

Fingerprint

Natural Killer Cells
Immunotherapy
Neoplasms
Epithelial-Mesenchymal Transition
HMGB1 Protein
Phenotype
Tumor Microenvironment
Immunosuppressive Agents
Biopsy

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies : New Hints for NK-Based Immunotherapy? / Cantoni, Claudia; Huergo-Zapico, Leticia; Parodi, M.; Pedrazzi, Marco; Mingari, Maria Cristina; Moretta, Alessandro; Sparatore, B.; Gonzalez, Segundo; Olive, Daniel; Bottino, Cristina; Castriconi, Roberta; Vitale, Massimo.

In: Journal of Immunology Research, Vol. 2016, 4684268, 2016.

Research output: Contribution to journalReview article

Cantoni, Claudia ; Huergo-Zapico, Leticia ; Parodi, M. ; Pedrazzi, Marco ; Mingari, Maria Cristina ; Moretta, Alessandro ; Sparatore, B. ; Gonzalez, Segundo ; Olive, Daniel ; Bottino, Cristina ; Castriconi, Roberta ; Vitale, Massimo. / NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies : New Hints for NK-Based Immunotherapy?. In: Journal of Immunology Research. 2016 ; Vol. 2016.
@article{908c04b5915443d0a994f4af8d505762,
title = "NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy?",
abstract = "Several evidences suggest that NK cells can patrol the body and eliminate tumors in their initial phases but may hardly control established solid tumors. Multiple factors, including the transition of tumor cells towards a proinvasive/prometastatic phenotype, the immunosuppressive effect of the tumor microenvironment, and the tumor structure complexity, may account for limited NK cell efficacy. Several putative mechanisms of NK cell suppression have been defined in these last years; conversely, the cross talk between NK cells and tumor cells undergoing different transitional phases remains poorly explored. Nevertheless, recent in vitro studies and immunohistochemical analyses on tumor biopsies suggest that NK cells could not only kill tumor cells but also influence their evolution. Indeed, NK cells may induce tumor cells to change the expression of HLA-I, PD-L1, or NKG2D-L and modulate their susceptibility to the immune response. Moreover, NK cells may be preferentially located in the borders of tumor masses, where, indeed, tumor cells can undergo Epithelial-to-Mesenchymal Transition (EMT) acquiring prometastatic phenotype. Finally, the recently highlighted role of HMGB1 both in EMT and in amplifying the recruitment of NK cells provides further hints on a possible effect of NK cells on tumor progression and fosters new studies on this issue.",
author = "Claudia Cantoni and Leticia Huergo-Zapico and M. Parodi and Marco Pedrazzi and Mingari, {Maria Cristina} and Alessandro Moretta and B. Sparatore and Segundo Gonzalez and Daniel Olive and Cristina Bottino and Roberta Castriconi and Massimo Vitale",
year = "2016",
doi = "10.1155/2016/4684268",
language = "English",
volume = "2016",
journal = "Journal of Immunology Research",
issn = "2314-8861",
publisher = "Hindawi Limited",

}

TY - JOUR

T1 - NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies

T2 - New Hints for NK-Based Immunotherapy?

AU - Cantoni, Claudia

AU - Huergo-Zapico, Leticia

AU - Parodi, M.

AU - Pedrazzi, Marco

AU - Mingari, Maria Cristina

AU - Moretta, Alessandro

AU - Sparatore, B.

AU - Gonzalez, Segundo

AU - Olive, Daniel

AU - Bottino, Cristina

AU - Castriconi, Roberta

AU - Vitale, Massimo

PY - 2016

Y1 - 2016

N2 - Several evidences suggest that NK cells can patrol the body and eliminate tumors in their initial phases but may hardly control established solid tumors. Multiple factors, including the transition of tumor cells towards a proinvasive/prometastatic phenotype, the immunosuppressive effect of the tumor microenvironment, and the tumor structure complexity, may account for limited NK cell efficacy. Several putative mechanisms of NK cell suppression have been defined in these last years; conversely, the cross talk between NK cells and tumor cells undergoing different transitional phases remains poorly explored. Nevertheless, recent in vitro studies and immunohistochemical analyses on tumor biopsies suggest that NK cells could not only kill tumor cells but also influence their evolution. Indeed, NK cells may induce tumor cells to change the expression of HLA-I, PD-L1, or NKG2D-L and modulate their susceptibility to the immune response. Moreover, NK cells may be preferentially located in the borders of tumor masses, where, indeed, tumor cells can undergo Epithelial-to-Mesenchymal Transition (EMT) acquiring prometastatic phenotype. Finally, the recently highlighted role of HMGB1 both in EMT and in amplifying the recruitment of NK cells provides further hints on a possible effect of NK cells on tumor progression and fosters new studies on this issue.

AB - Several evidences suggest that NK cells can patrol the body and eliminate tumors in their initial phases but may hardly control established solid tumors. Multiple factors, including the transition of tumor cells towards a proinvasive/prometastatic phenotype, the immunosuppressive effect of the tumor microenvironment, and the tumor structure complexity, may account for limited NK cell efficacy. Several putative mechanisms of NK cell suppression have been defined in these last years; conversely, the cross talk between NK cells and tumor cells undergoing different transitional phases remains poorly explored. Nevertheless, recent in vitro studies and immunohistochemical analyses on tumor biopsies suggest that NK cells could not only kill tumor cells but also influence their evolution. Indeed, NK cells may induce tumor cells to change the expression of HLA-I, PD-L1, or NKG2D-L and modulate their susceptibility to the immune response. Moreover, NK cells may be preferentially located in the borders of tumor masses, where, indeed, tumor cells can undergo Epithelial-to-Mesenchymal Transition (EMT) acquiring prometastatic phenotype. Finally, the recently highlighted role of HMGB1 both in EMT and in amplifying the recruitment of NK cells provides further hints on a possible effect of NK cells on tumor progression and fosters new studies on this issue.

UR - http://www.scopus.com/inward/record.url?scp=84971572890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971572890&partnerID=8YFLogxK

U2 - 10.1155/2016/4684268

DO - 10.1155/2016/4684268

M3 - Review article

VL - 2016

JO - Journal of Immunology Research

JF - Journal of Immunology Research

SN - 2314-8861

M1 - 4684268

ER -